Peptron Inc
KOSDAQ:087010
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Waste Management Inc
NYSE:WM
|
US |
Peptron Inc
Interest Expense
Peptron Inc
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Interest Expense
₩1.8B
|
CAGR 3-Years
52%
|
CAGR 5-Years
147%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Interest Expense
₩4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
44%
|
CAGR 10-Years
-1%
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Interest Expense
₩971.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Interest Expense
₩883.2m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
Peptron Inc
Glance View
Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care. At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.
